SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14, 2026, at 2:15 p.m. PT. 44th Annual J.P. Morgan Healthcare Conference – Company PresentationDate: Wednes ...

Core Insights - Perspective Therapeutics, Inc. announced that updated data on its [Pb]VMT-α-NET program will be presented at the ASCO-GI Congress 2026, scheduled for January 8 to 10, 2026 [1][2] Group 1: Company Overview - Perspective Therapeutics is focused on developing advanced radiopharmaceutical treatments for various cancers, utilizing proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells [4][5] - The company is conducting a multi-center, open-label, dose-escalation study of [Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors [3][4] Group 2: Clinical Data and Efficacy - As of the data cut-off date of September 12, 2025, safety findings from 55 patients indicated a favorable safety profile for [²¹²Pb]VMT-α-NET, with no dose-limiting toxicities or Grade 4 or 5 treatment-emergent adverse events reported [4][6] - Among 25 patients evaluated, 20 (80%) remained progression-free, and 8 patients achieved confirmed responses, all from Cohort 2, with a median follow-up of 41 weeks [6]

SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: Piper Sandler & Co. 37th Annual Healthcare Conference – Fireside ChatDate: Tuesday ...

Core Insights - Perspective Therapeutics, Inc. is a radiopharmaceutical development company focused on advanced cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb for targeted radiation delivery to cancer cells [2][3] Company Overview - The company is pioneering advanced treatments for various cancers and is developing complementary imaging diagnostics that utilize the same targeting moieties, allowing for personalized treatment and optimized patient outcomes [2] - The "theranostic" approach enables visualization of specific tumors followed by targeted treatment, potentially improving efficacy and minimizing toxicity [2] Clinical Development - The company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are currently in Phase 1/2a imaging and therapy trials in the U.S. [3] - Perspective Therapeutics is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to provide patient-ready product candidates for clinical trials and commercial operations [3] Upcoming Events - Members of the senior leadership team will participate in the Truist Securities BioPharma Symposium on November 6, 2025, in New York, NY, for one-on-one meetings with investors [1] - The company will also be featured in a Fireside Chat at the UBS Global Healthcare Conference on November 11, 2025, from 4:15 to 4:50 p.m. ET in Palm Beach, FL [2]

Core Insights - The FDA has set a Prescription Drug User Fee Act (PDUFA) date of March 29, 2026, for Lantheus Holdings' LNTH-2501, a diagnostic kit for neuroendocrine tumors [1][2] Company Overview - Lantheus Holdings, Inc. is a leading radiopharmaceutical-focused company dedicated to improving patient outcomes through innovative diagnostic solutions [5] - The company has been providing radiopharmaceutical solutions for nearly 70 years and operates globally with offices in multiple countries [5] Product Details - LNTH-2501 (Gallium-68 edotreotide) is designed for use with positron emission tomography (PET) imaging to localize somatostatin receptor-positive neuroendocrine tumors (SSTR+ NETs) in both adult and pediatric patients [1][4] - The product is submitted under the FDA's 505(b)(2) pathway, supported by extensive evidence from multiple published studies [2][4] - If approved, LNTH-2501 may complement Lantheus' therapeutic candidate PNT2003, enhancing the company's strategy for integrated diagnostic and therapeutic solutions [4] Market Context - Neuroendocrine tumors (NETs) are rare cancers, with over 170,000 individuals in the U.S. living with these conditions, and gastroenteropancreatic NETs (GEP-NETs) account for 55-70% of cases [3] - Due to their slow growth and non-specific symptoms, up to 50% of NETs are initially misdiagnosed, leading to delays in treatment [3]

Core Insights - Perspective Therapeutics, Inc. is set to report its third quarter 2025 financial results and provide a business update on November 10, 2025, after market close [1] Company Overview - Perspective Therapeutics, Inc. specializes in radiopharmaceutical development, focusing on advanced cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells [2] - The company is also developing complementary imaging diagnostics that utilize the same targeting moieties, allowing for personalized treatment and optimized patient outcomes through a "theranostic" approach [2] Clinical Programs - The company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are currently in Phase 1/2a imaging and therapy trials in the U.S. [3] - Perspective Therapeutics is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to provide patient-ready products for clinical trials and commercial operations [3]

Core Insights - Perspective Therapeutics, Inc. announced updated interim results from its Phase 1/2a clinical trial of [Pb]VMT-α-NET for treating unresectable or metastatic neuroendocrine tumors (NETs) at the ESMO Congress 2025 [1][2] Clinical Trial Results - The interim results were based on a data cut-off date of September 12, 2025, involving 55 patients across three dose cohorts who received at least one treatment of VMT-α-NET [2] - The objective response rate was reported at 44% (7 of 16 patients) in Cohort 2, with a median follow-up of 41 weeks, and 14 out of 16 patients remained free from progression [5][6] - Safety findings indicated no dose-limiting toxicities, no treatment-related discontinuations, and no serious renal complications among the patients [6] Expert Commentary - Richard Wahl, a professor at Washington University, highlighted the durable anti-tumor activity and excellent tolerability of [Pb]VMT-α-NET, emphasizing its potential as a treatment option for progressive NETs [4] - Markus Puhlmann, Chief Medical Officer, noted the compelling clinical profile of VMT-α-NET at the 5 mCi dose and the importance of the study for future registration [4] Future Developments - Initial efficacy data for an additional 23 patients in Cohort 2 and 8 patients in Cohort 3 are expected to be presented in 2026 [5][9] - The company is exploring whether a higher dose or refined patient selection criteria could enhance VMT-α-NET's clinical profile [7] Financial Position - As of September 30, 2025, the company's cash, cash equivalents, and short-term investments were approximately $174.1 million, expected to fund operations into late 2026 [8]

Core Insights - Perspective Therapeutics, Inc. has appointed Maya Martinez-Davis as an independent director to its Board of Directors, effective immediately [1][3] - Ms. Martinez-Davis brings extensive experience in the pharmaceutical industry, having held leadership roles at GSK, Merck KGaA, and Pfizer, particularly in oncology and specialty products [2][3] - The company is focused on pioneering advanced radiopharmaceutical treatments for cancer, utilizing proprietary technology that employs alpha-emitting isotopes for targeted therapy [4][5] Company Overview - Perspective Therapeutics specializes in radiopharmaceuticals aimed at treating various cancers, leveraging alpha-emitting isotopes to deliver radiation directly to cancer cells [4] - The company is developing complementary imaging diagnostics to personalize treatment and optimize patient outcomes through a "theranostic" approach [4] - Current clinical-stage programs include treatments for neuroendocrine tumors (VMT-α-NET), melanoma (VMT01), and solid tumors (PSV359), which are in Phase 1/2a trials in the U.S. [5] Leadership and Strategic Direction - Lori Woods, Chairperson of Perspective, expressed enthusiasm about Ms. Martinez-Davis joining the board, highlighting her complementary experience to existing directors and management [3] - Ms. Martinez-Davis aims to contribute insights to advance the company's clinical programs and enhance shareholder value [3] - CEO Thijs Spoor emphasized the potential of the company's innovative science to develop new medicines that could significantly improve patient lives [3]

Core Insights - Perspective Therapeutics, Inc. is a radiopharmaceutical company focused on advanced cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells specifically [3][4] - The company is actively participating in several upcoming healthcare conferences to engage with investors and discuss its innovative therapies [1][2] Company Overview - Perspective Therapeutics is pioneering advanced treatments for various cancers, utilizing a "theranostic" approach that combines therapy and diagnostics to personalize treatment and optimize patient outcomes [3] - The company is developing imaging diagnostics that work alongside its therapeutic products, enhancing the ability to visualize and treat tumors effectively [3] Clinical Development - The company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are currently in Phase 1/2a imaging and therapy trials in the U.S. [4] - Perspective Therapeutics is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to ensure the delivery of patient-ready products for clinical trials and commercial operations [4]

Core Insights - Perspective Therapeutics, Inc. announced that updated data on its [Pb]VMT-α-NET program will be presented at the ESMO Congress 2025 in Berlin, Germany from October 17 to 21, 2025 [1] - The presentation will include mature safety and preliminary efficacy data for advanced somatostatin receptor 2 positive neuroendocrine tumors [2] Company Overview - Perspective Therapeutics is a radiopharmaceutical company focused on developing advanced cancer treatments using alpha-emitting isotopes to target cancer cells [4] - The company is also developing imaging diagnostics that complement its therapeutic approaches, enhancing treatment personalization and patient outcomes through a "theranostic" strategy [4] Clinical Programs - The [Pb]VMT-α-NET program is currently in a multi-center, open-label, dose-escalation study for patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors [3] - The study has reported interim updates, with a data cut-off date of April 30, 2025, and additional patients enrolled after reopening Cohort 2 in August 2024 [3] Future Developments - The company is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to facilitate clinical trials and commercial operations [5]